OA11505A - Therapeutic combinations of (selective) estrogen receptor modulators (SERM) and growth hormone secretagogues (GHS) for treating musculoskeletal frailty. - Google Patents

Therapeutic combinations of (selective) estrogen receptor modulators (SERM) and growth hormone secretagogues (GHS) for treating musculoskeletal frailty. Download PDF

Info

Publication number: OA11505A
Authority: OA; OAPI
Prior art keywords: phenyl; oxo; bone; compound; ethoxy
Prior art date: 1998-06-16

Application number

OA1200000290A

Other languages

English (en)

Inventor

Hua Zhu Ke

Mei Li

Lydia Codetta Pan

David Duane Thompson

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-06-16

Filing date

2000-10-20

Publication date

2004-05-07

2000-10-20 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2004-05-07 Publication of OA11505A publication Critical patent/OA11505A/en

Links

208000036119 Frailty Diseases 0.000 title claims abstract description 14
206010003549 asthenia Diseases 0.000 title claims abstract description 14
239000003324 growth hormone secretagogue Substances 0.000 title description 6
239000002834 estrogen receptor modulator Substances 0.000 title description 4
230000001225 therapeutic effect Effects 0.000 title description 3
239000000333 selective estrogen receptor modulator Substances 0.000 title 1
229940095743 selective estrogen receptor modulator Drugs 0.000 title 1
210000000988 bone and bone Anatomy 0.000 claims abstract description 53
208000001132 Osteoporosis Diseases 0.000 claims abstract description 23
KVLLHLWBPNCVNR-SKCUWOTOSA-N capromorelin Chemical compound C([C@@]12CN(CCC1=NN(C2=O)C)C(=O)[C@@H](COCC=1C=CC=CC=1)NC(=O)C(C)(C)N)C1=CC=CC=C1 KVLLHLWBPNCVNR-SKCUWOTOSA-N 0.000 claims abstract description 7
GXESHMAMLJKROZ-IAPPQJPRSA-N lasofoxifene Chemical compound C1([C@@H]2[C@@H](C3=CC=C(C=C3CC2)O)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 GXESHMAMLJKROZ-IAPPQJPRSA-N 0.000 claims abstract description 7
150000001875 compounds Chemical class 0.000 claims description 50
229940047889 isobutyramide Drugs 0.000 claims description 18
241000124008 Mammalia Species 0.000 claims description 15
239000008194 pharmaceutical composition Substances 0.000 claims description 12
208000010392 Bone Fractures Diseases 0.000 claims description 10
206010065687 Bone loss Diseases 0.000 claims description 9
239000002552 dosage form Substances 0.000 claims description 7
FEWJPZIEWOKRBE-LWMBPPNESA-L D-tartrate(2-) Chemical compound [O-]C(=O)[C@@H](O)[C@H](O)C([O-])=O FEWJPZIEWOKRBE-LWMBPPNESA-L 0.000 claims description 6
239000003085 diluting agent Substances 0.000 claims description 5
230000035876 healing Effects 0.000 claims description 4
FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 claims description 3
201000001245 periodontitis Diseases 0.000 claims description 3
201000010814 Synostosis Diseases 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims description 2
WRASVFOICVIUGY-UHFFFAOYSA-N 1-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol Chemical compound OC1=CC=C2CCCCC2=C1C(C=C1)=CC=C1OCCN1CCCC1 WRASVFOICVIUGY-UHFFFAOYSA-N 0.000 claims 1
MJGRJCMGMFLOET-MYPSAZMDSA-N n-[(2r)-1-[(3ar)-3a-benzyl-2-methyl-3-oxo-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-5-yl]-1-oxo-3-phenylmethoxypropan-2-yl]-2-amino-2-methylpropanamide;(2r,3r)-2,3-dihydroxybutanedioic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C([C@@]12CN(CCC1=NN(C2=O)C)C(=O)[C@@H](COCC=1C=CC=CC=1)NC(=O)C(C)(C)N)C1=CC=CC=C1 MJGRJCMGMFLOET-MYPSAZMDSA-N 0.000 claims 1
238000000034 method Methods 0.000 abstract description 32
239000000203 mixture Substances 0.000 abstract description 16
210000003205 muscle Anatomy 0.000 abstract description 11
150000003839 salts Chemical class 0.000 abstract description 8
208000001164 Osteoporotic Fractures Diseases 0.000 abstract description 3
102000018997 Growth Hormone Human genes 0.000 description 30
108010051696 Growth Hormone Proteins 0.000 description 30
239000000122 growth hormone Substances 0.000 description 30
230000000694 effects Effects 0.000 description 15
241000700159 Rattus Species 0.000 description 14
229940011871 estrogen Drugs 0.000 description 13
239000000262 estrogen Substances 0.000 description 13
239000002775 capsule Substances 0.000 description 12
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
230000001965 increasing effect Effects 0.000 description 11
239000003795 chemical substances by application Substances 0.000 description 10
238000011282 treatment Methods 0.000 description 9
206010017076 Fracture Diseases 0.000 description 7
230000007423 decrease Effects 0.000 description 7
201000010099 disease Diseases 0.000 description 7
210000002468 fat body Anatomy 0.000 description 7
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
238000003556 assay Methods 0.000 description 5
238000011888 autopsy Methods 0.000 description 5
230000008901 benefit Effects 0.000 description 5
230000003247 decreasing effect Effects 0.000 description 5
239000011888 foil Substances 0.000 description 5
239000007864 aqueous solution Substances 0.000 description 4
208000035475 disorder Diseases 0.000 description 4
229940079593 drug Drugs 0.000 description 4
239000003814 drug Substances 0.000 description 4
239000000463 material Substances 0.000 description 4
229920003023 plastic Polymers 0.000 description 4
GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 4
230000000580 secretagogue effect Effects 0.000 description 4
206010062767 Hypophysitis Diseases 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
206010028980 Neoplasm Diseases 0.000 description 3
230000037182 bone density Effects 0.000 description 3
201000011510 cancer Diseases 0.000 description 3
230000007812 deficiency Effects 0.000 description 3
238000009547 dual-energy X-ray absorptiometry Methods 0.000 description 3
230000036541 health Effects 0.000 description 3
WFKAJVHLWXSISD-UHFFFAOYSA-N isobutyramide Chemical compound CC(C)C(N)=O WFKAJVHLWXSISD-UHFFFAOYSA-N 0.000 description 3
150000002632 lipids Chemical class 0.000 description 3
230000001817 pituitary effect Effects 0.000 description 3
210000003635 pituitary gland Anatomy 0.000 description 3
239000004033 plastic Substances 0.000 description 3
229960004622 raloxifene Drugs 0.000 description 3
239000000243 solution Substances 0.000 description 3
230000004936 stimulating effect Effects 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
-1 3a(R)-benzyl-2-methyl-3-oxo-2,3,3a,4,6,7-hexahydro-pyrazolo[4,3-c]pyridin-5-yl Chemical group 0.000 description 2
206010006187 Breast cancer Diseases 0.000 description 2
208000026310 Breast neoplasm Diseases 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
ZQZFYGIXNQKOAV-OCEACIFDSA-N Droloxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 ZQZFYGIXNQKOAV-OCEACIFDSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
102000015779 HDL Lipoproteins Human genes 0.000 description 2
108010010234 HDL Lipoproteins Proteins 0.000 description 2
IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
239000000556 agonist Substances 0.000 description 2
230000037396 body weight Effects 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
230000008859 change Effects 0.000 description 2
229960002986 dinoprostone Drugs 0.000 description 2
XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 2
229950004203 droloxifene Drugs 0.000 description 2
150000004677 hydrates Chemical class 0.000 description 2
210000003016 hypothalamus Anatomy 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
230000008520 organization Effects 0.000 description 2
230000011164 ossification Effects 0.000 description 2
238000004806 packaging method and process Methods 0.000 description 2
239000006187 pill Substances 0.000 description 2
208000001685 postmenopausal osteoporosis Diseases 0.000 description 2
XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
239000003488 releasing hormone Substances 0.000 description 2
229940089617 risedronate Drugs 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
229940095064 tartrate Drugs 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
VIYKYVYAKVNDPS-HKGPVOKGSA-N (2s)-2-azanyl-3-[3,4-bis(oxidanyl)phenyl]propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 VIYKYVYAKVNDPS-HKGPVOKGSA-N 0.000 description 1
125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 description 1
208000007848 Alcoholism Diseases 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
102100033367 Appetite-regulating hormone Human genes 0.000 description 1
101710111255 Appetite-regulating hormone Proteins 0.000 description 1
235000017060 Arachis glabrata Nutrition 0.000 description 1
244000105624 Arachis hypogaea Species 0.000 description 1
235000010777 Arachis hypogaea Nutrition 0.000 description 1
235000018262 Arachis monticola Nutrition 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
208000020084 Bone disease Diseases 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
206010013883 Dwarfism Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
102000051325 Glucagon Human genes 0.000 description 1
108060003199 Glucagon Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
206010020100 Hip fracture Diseases 0.000 description 1
208000013016 Hypoglycemia Diseases 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
240000003183 Manihot esculenta Species 0.000 description 1
235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
102000003982 Parathyroid hormone Human genes 0.000 description 1
108090000445 Parathyroid hormone Proteins 0.000 description 1
208000023146 Pre-existing disease Diseases 0.000 description 1
KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
244000000231 Sesamum indicum Species 0.000 description 1
235000003434 Sesamum indicum Nutrition 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
244000061456 Solanum tuberosum Species 0.000 description 1
235000002595 Solanum tuberosum Nutrition 0.000 description 1
102000005157 Somatostatin Human genes 0.000 description 1
108010056088 Somatostatin Proteins 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
208000002495 Uterine Neoplasms Diseases 0.000 description 1
206010046782 Uterine enlargement Diseases 0.000 description 1
GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
102000002852 Vasopressins Human genes 0.000 description 1
108010004977 Vasopressins Proteins 0.000 description 1
206010048049 Wrist fracture Diseases 0.000 description 1
230000009471 action Effects 0.000 description 1
210000000577 adipose tissue Anatomy 0.000 description 1
230000032683 aging Effects 0.000 description 1
206010001584 alcohol abuse Diseases 0.000 description 1
208000025746 alcohol use disease Diseases 0.000 description 1
239000003263 anabolic agent Substances 0.000 description 1
229940124325 anabolic agent Drugs 0.000 description 1
230000001195 anabolic effect Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
230000003416 augmentation Effects 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000002617 bone density conservation agent Substances 0.000 description 1
230000008416 bone turnover Effects 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
230000025938 carbohydrate utilization Effects 0.000 description 1
238000012754 cardiac puncture Methods 0.000 description 1
238000011278 co-treatment Methods 0.000 description 1
239000003086 colorant Substances 0.000 description 1
230000001054 cortical effect Effects 0.000 description 1
230000007547 defect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
210000004696 endometrium Anatomy 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
239000000328 estrogen antagonist Substances 0.000 description 1
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
238000000605 extraction Methods 0.000 description 1
230000001815 facial effect Effects 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
FATAVLOOLIRUNA-UHFFFAOYSA-N formylmethyl Chemical group [CH2]C=O FATAVLOOLIRUNA-UHFFFAOYSA-N 0.000 description 1
235000021588 free fatty acids Nutrition 0.000 description 1
230000006870 function Effects 0.000 description 1
238000003304 gavage Methods 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
229960004666 glucagon Drugs 0.000 description 1
239000003862 glucocorticoid Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
230000002218 hypoglycaemic effect Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000004973 liquid crystal related substance Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000005541 medical transmission Effects 0.000 description 1
230000004066 metabolic change Effects 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
210000004165 myocardium Anatomy 0.000 description 1
239000007922 nasal spray Substances 0.000 description 1
229940097496 nasal spray Drugs 0.000 description 1
238000012858 packaging process Methods 0.000 description 1
238000002638 palliative care Methods 0.000 description 1
239000000199 parathyroid hormone Substances 0.000 description 1
229960001319 parathyroid hormone Drugs 0.000 description 1
230000037361 pathway Effects 0.000 description 1
235000020232 peanut Nutrition 0.000 description 1
125000001151 peptidyl group Chemical group 0.000 description 1
208000028169 periodontal disease Diseases 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
239000000902 placebo Substances 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000003825 pressing Methods 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
210000002307 prostate Anatomy 0.000 description 1
238000001243 protein synthesis Methods 0.000 description 1
230000010490 psychological well-being Effects 0.000 description 1
230000000541 pulsatile effect Effects 0.000 description 1
BKXVVCILCIUCLG-UHFFFAOYSA-N raloxifene hydrochloride Chemical compound [H+].[Cl-].C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 BKXVVCILCIUCLG-UHFFFAOYSA-N 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
238000009256 replacement therapy Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
238000012216 screening Methods 0.000 description 1
230000000276 sedentary effect Effects 0.000 description 1
150000004760 silicates Chemical class 0.000 description 1
210000002027 skeletal muscle Anatomy 0.000 description 1
230000000391 smoking effect Effects 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
229960000553 somatostatin Drugs 0.000 description 1
210000001875 somatotroph Anatomy 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
238000011285 therapeutic regimen Methods 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
238000004448 titration Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
239000006211 transdermal dosage form Substances 0.000 description 1
230000014616 translation Effects 0.000 description 1
206010046766 uterine cancer Diseases 0.000 description 1
229960003726 vasopressin Drugs 0.000 description 1
230000004584 weight gain Effects 0.000 description 1
235000019786 weight gain Nutrition 0.000 description 1
BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
229960001600 xylazine Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Physical Education & Sports Medicine (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

OA1200000290A 1998-06-16 2000-10-20 Therapeutic combinations of (selective) estrogen receptor modulators (SERM) and growth hormone secretagogues (GHS) for treating musculoskeletal frailty. OA11505A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US8946998P	1998-06-16	1998-06-16

Publications (1)

Publication Number	Publication Date
OA11505A true OA11505A (en)	2004-05-07

Family

ID=22217825

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA1200000290A OA11505A (en)	1998-06-16	2000-10-20	Therapeutic combinations of (selective) estrogen receptor modulators (SERM) and growth hormone secretagogues (GHS) for treating musculoskeletal frailty.

Country Status (30)

Country	Link
EP (1)	EP1087764A1 (fr)
JP (1)	JP2002518326A (fr)
KR (1)	KR20010052852A (fr)
CN (1)	CN1301160A (fr)
AP (1)	AP9901582A0 (fr)
AR (1)	AR018869A1 (fr)
AU (1)	AU4054799A (fr)
BG (1)	BG105041A (fr)
BR (1)	BR9911324A (fr)
CA (1)	CA2335134A1 (fr)
CO (1)	CO5070587A1 (fr)
EA (1)	EA200001186A1 (fr)
GT (1)	GT199900087A (fr)
HN (1)	HN1999000097A (fr)
HR (1)	HRP20000859A2 (fr)
HU (1)	HUP0102505A3 (fr)
ID (1)	ID27599A (fr)
IL (1)	IL138630A0 (fr)
IS (1)	IS5691A (fr)
MA (1)	MA26652A1 (fr)
NO (1)	NO20006312L (fr)
OA (1)	OA11505A (fr)
PA (1)	PA8475901A1 (fr)
PE (1)	PE20000646A1 (fr)
PL (1)	PL344981A1 (fr)
SK (1)	SK18912000A3 (fr)
TN (1)	TNSN99124A1 (fr)
TR (1)	TR200003544T2 (fr)
WO (1)	WO1999065486A1 (fr)
ZA (1)	ZA993975B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2000047735A2 (fr) *	1999-02-08	2000-08-17	Mcgill University	ANIMAL TRANSGENIQUE NON-HUMAIN DONT LES CELLULES GERMINALES ET SOMATIQUES CONTIENNENT UNE MUTATION KNOCKOUT DANS L'ADN CODANT LE RECEPTEUR NUCLEAIRE ORPHELIN ERR$g(a)
ES2274854T3 (es)	2000-05-08	2007-06-01	Pfizer Products Inc.	Resolucion enzimatica de moduladores selectivos del receptor de estrogeno.
IL145106A0 (en) *	2000-08-30	2002-06-30	Pfizer Prod Inc	Intermittent administration of a geowth hormone secretagogue
MXPA03001771A (es)	2000-08-30	2003-06-04	Pfizer Prod Inc	Formulaciones de liberacion sostenida para secretagogos de hormona del crecimiento.
US7476653B2 (en)	2003-06-18	2009-01-13	Tranzyme Pharma, Inc.	Macrocyclic modulators of the ghrelin receptor
WO2006024931A2 (fr) *	2004-08-31	2006-03-09	Pfizer Products Inc.	Combinaisons therapeutiques comprenant un modulateur selectif du recepteur d'oestrogenes et un modulateur selectif du recepteur d'androgenes
CU23558A1 (es)	2006-02-28	2010-07-20	Ct Ingenieria Genetica Biotech	Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
EP2644618B1 (fr)	2007-02-09	2016-08-17	Ocera Therapeutics, Inc.	Intermédaires dans la synthese de modulateurs macrocycliques du récepteur de la ghréline

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UA51676C2 (uk) *	1995-11-02	2002-12-16	Пфайзер Інк.	(-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція
TW432073B (en) *	1995-12-28	2001-05-01	Pfizer	Pyrazolopyridine compounds
HN1996000101A (es) *	1996-02-28	1997-06-26	Inc Pfizer	Terapia combinada para la osteoporosis

1999
- 1999-06-15 PA PA19998475901A patent/PA8475901A1/es unknown
- 1999-06-15 AP APAP/P/1999/001582A patent/AP9901582A0/en unknown
- 1999-06-15 PE PE1999000528A patent/PE20000646A1/es not_active Application Discontinuation
- 1999-06-15 AR ARP990102848A patent/AR018869A1/es not_active Application Discontinuation
- 1999-06-15 HN HN1999000097A patent/HN1999000097A/es unknown
- 1999-06-15 ZA ZA9903975A patent/ZA993975B/xx unknown
- 1999-06-16 HU HU0102505A patent/HUP0102505A3/hu unknown
- 1999-06-16 EP EP99923802A patent/EP1087764A1/fr not_active Withdrawn
- 1999-06-16 GT GT199900087A patent/GT199900087A/es unknown
- 1999-06-16 TN TNTNSN99124A patent/TNSN99124A1/fr unknown
- 1999-06-16 CO CO99037622A patent/CO5070587A1/es unknown
- 1999-06-16 EA EA200001186A patent/EA200001186A1/ru unknown
- 1999-06-16 TR TR2000/03544T patent/TR200003544T2/xx unknown
- 1999-06-16 AU AU40547/99A patent/AU4054799A/en not_active Abandoned
- 1999-06-16 BR BR9911324-4A patent/BR9911324A/pt not_active Application Discontinuation
- 1999-06-16 KR KR1020007014186A patent/KR20010052852A/ko not_active Ceased
- 1999-06-16 HR HR20000859A patent/HRP20000859A2/hr not_active Application Discontinuation
- 1999-06-16 WO PCT/IB1999/001117 patent/WO1999065486A1/fr not_active Ceased
- 1999-06-16 PL PL99344981A patent/PL344981A1/xx not_active Application Discontinuation
- 1999-06-16 JP JP2000554366A patent/JP2002518326A/ja active Pending
- 1999-06-16 CN CN99806237A patent/CN1301160A/zh active Pending
- 1999-06-16 MA MA25628A patent/MA26652A1/fr unknown
- 1999-06-16 ID IDW20002627A patent/ID27599A/id unknown
- 1999-06-16 IL IL13863099A patent/IL138630A0/xx unknown
- 1999-06-16 SK SK1891-2000A patent/SK18912000A3/sk unknown
- 1999-06-16 CA CA002335134A patent/CA2335134A1/fr not_active Abandoned
2000
- 2000-10-20 OA OA1200000290A patent/OA11505A/en unknown
- 2000-10-27 IS IS5691A patent/IS5691A/is unknown
- 2000-12-11 BG BG105041A patent/BG105041A/xx unknown
- 2000-12-12 NO NO20006312A patent/NO20006312L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
MA26652A1 (fr)	2004-12-20
HUP0102505A3 (en)	2002-12-28
PE20000646A1 (es)	2000-08-05
ID27599A (id)	2001-04-12
AP9901582A0 (en)	1999-06-30
SK18912000A3 (sk)	2001-10-08
GT199900087A (es)	2000-12-07
EP1087764A1 (fr)	2001-04-04
HN1999000097A (es)	1999-11-03
BG105041A (en)	2001-08-31
TNSN99124A1 (fr)	2005-11-10
ZA993975B (en)	2000-12-15
PA8475901A1 (es)	2000-05-24
CA2335134A1 (fr)	1999-12-23
EA200001186A1 (ru)	2001-06-25
AR018869A1 (es)	2001-12-12
IS5691A (is)	2000-10-27
TR200003544T2 (tr)	2001-04-20
HUP0102505A2 (hu)	2001-11-28
IL138630A0 (en)	2001-10-31
JP2002518326A (ja)	2002-06-25
PL344981A1 (en)	2001-11-19
NO20006312D0 (no)	2000-12-12
NO20006312L (no)	2000-12-12
CO5070587A1 (es)	2001-08-28
WO1999065486A1 (fr)	1999-12-23
BR9911324A (pt)	2001-04-03
AU4054799A (en)	2000-01-05
CN1301160A (zh)	2001-06-27
KR20010052852A (ko)	2001-06-25
HRP20000859A2 (en)	2001-04-30

Publication	Publication Date	Title
ES2433476T3 (es)	2013-12-11	Combinaciones que contienen inhibidores de la dipeptidilpeptidasa-IV y agentes 5 antidiabéticos
ES2312169T3 (es)	2009-02-16	Terapia combinada para osteoporosis.
JP2003528135A (ja)	2003-09-24	糖尿病のランゲルハンス島シグナリングの改善方法及びその防止方法
US6132774A (en)	2000-10-17	Therapeutic combinations comprising a selective estrogen receptor modulator and parathyroid hormone
OA11505A (en)	2004-05-07	Therapeutic combinations of (selective) estrogen receptor modulators (SERM) and growth hormone secretagogues (GHS) for treating musculoskeletal frailty.
US20020002137A1 (en)	2002-01-03	Combination of growth hormone secretagogues and antidepressants
CA2565368A1 (fr)	2005-11-24	Preparations orales contenant des proteines morphogenetiques osseuses pour le traitement de maladies osseuses metaboliques
WO1999065488A1 (fr)	1999-12-23	Combinaisons therapeutiques de modulateurs (selectifs) des recepteurs des oestrogenes (serm) et de secretagogues d'hormones de croissance (ghs) pour traiter la fragilite musculo-squelettique
EP0966968B1 (fr)	2004-05-06	Combinaisons thérapeutiques contenant un modulateur sélectif du récepteur oestrogénique et de la prostaglandine E2
JP2007505892A (ja)	2007-03-15	向上した成長障害の処置方法
HK1036414A (en)	2002-01-04	Therapeutic combinations of (selective) estrogen receptor modulators (serm) and growth hormone secretagogues (ghs) for treating musculoskeletal frailty
CZ20004679A3 (cs)	2001-05-16	Terapeutické kombinace (selektivních) modulátorů estrogenního receptoru (ŠERM) a prostředků podporujících sekreci růstového hormonu (GHS) pro léčbu muskuloskeletární fragility
MXPA00012727A (en)	2001-07-31	Therapeutic combinations of (selective) estrogen receptor modulators (serm) and growth hormone secretagogues (ghs) for treating musculoskeletal frailty
JPH04282313A (ja)	1992-10-07	血圧降下剤
CZ20004680A3 (cs)	2001-06-13	Terapeutické kombinace (selektivních) modulátorů estrogenního receptorů (ŠERM) a prostředků podporujících sekreci růstového hormonu (GHS) pro léčbu muskuloskeletární fragility
MXPA00012628A (en)	2001-07-31	Therapeutic combinations of (selective) estrogen receptor modulators (serm) and growth hormone secretagogues (ghs) for treating musculoskeletal frailty
HK1036938A (en)	2002-01-25	Therapeutic combinations of (selective) estrogen receptor modulators (serm) and growth hormone secretagogues (ghs) for treating musculoskeletal frailty
MXPA00012728A (en)	2001-07-31	Therapeutic combinations comprising a selective estrogen receptor modulator and parathyroid hormone
JPH10203995A (ja)	1998-08-04	抗骨粗鬆症剤
MXPA99005564A (en)	2000-11-01	Therapeutic combinations comprising a selective estrogen receptor modulator and prostaglandin e2